X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2017 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Abbott India with Biocon Ltd - Equitymaster
  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

ABBOTT INDIA vs BIOCON LTD - Comparison Results

ABBOTT INDIA    Change

Formerly known as Knoll Pharmaceuticals Limited, Abbott India Limited (AIL) is a subsidiary of Abbott Capital India Limited in which the latter holds about 69% stake. It is involved in the discovery, development, manufacture and marketing of pharmace... More

BIOCON LTD 
   Change

Biocon is India's largest biotechnology company with presence in biopharmaceuticals, custom research and clinical research. It started as an enzymes manufacturer and later evolved into an integrated biopharmaceutical company. The company has two subs... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    ABBOTT INDIA BIOCON LTD ABBOTT INDIA/
BIOCON LTD
 
P/E (TTM) x 32.8 36.6 89.8% View Chart
P/BV x 8.2 4.9 168.7% View Chart
Dividend Yield % 0.8 1.5 53.8%  

Financials

 ABBOTT INDIA   BIOCON LTD
EQUITY SHARE DATA
    ABBOTT INDIA
Mar-16
BIOCON LTD
Mar-16
ABBOTT INDIA/
BIOCON LTD
5-Yr Chart
Click to enlarge
High Rs6,015496 1,213.4%   
Low Rs3,707397 934.9%   
Sales per share (Unadj.) Rs1,236.9174.3 709.8%  
Earnings per share (Unadj.) Rs122.244.8 272.7%  
Cash flow per share (Unadj.) Rs129.056.9 226.6%  
Dividends per share (Unadj.) Rs35.005.00 700.0%  
Dividend yield (eoy) %0.71.1 64.2%  
Book value per share (Unadj.) Rs521.2202.8 257.0%  
Shares outstanding (eoy) m21.25200.00 10.6%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x3.92.6 153.5%   
Avg P/E ratio x39.810.0 399.6%  
P/CF ratio (eoy) x37.77.8 480.9%  
Price / Book Value ratio x9.32.2 423.9%  
Dividend payout %28.611.2 256.7%   
Avg Mkt Cap Rs m103,29689,220 115.8%   
No. of employees `0003.04.4 67.0%   
Total wages/salary Rs m3,3706,363 53.0%   
Avg. sales/employee Rs Th8,891.87,894.5 112.6%   
Avg. wages/employee Rs Th1,140.01,441.2 79.1%   
Avg. net profit/employee Rs Th878.32,029.7 43.3%   
INCOME DATA
Net Sales Rs m26,28434,854 75.4%  
Other income Rs m504845 59.7%   
Total revenues Rs m26,78935,699 75.0%   
Gross profit Rs m3,6658,200 44.7%  
Depreciation Rs m1442,423 6.0%   
Interest Rs m8102 7.9%   
Profit before tax Rs m4,0176,520 61.6%   
Minority Interest Rs m0-744 0.0%   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m05,754 0.0%   
Tax Rs m1,4212,569 55.3%   
Profit after tax Rs m2,5968,961 29.0%  
Gross profit margin %13.923.5 59.3%  
Effective tax rate %35.439.4 89.8%   
Net profit margin %9.925.7 38.4%  
BALANCE SHEET DATA
Current assets Rs m14,44639,932 36.2%   
Current liabilities Rs m4,72516,276 29.0%   
Net working cap to sales %37.067.9 54.5%  
Current ratio x3.12.5 124.6%  
Inventory Days Days5154 96.0%  
Debtors Days Days2086 22.7%  
Net fixed assets Rs m1,11339,101 2.8%   
Share capital Rs m2131,000 21.3%   
"Free" reserves Rs m10,80838,591 28.0%   
Net worth Rs m11,07640,556 27.3%   
Long term debt Rs m020,724 0.0%   
Total assets Rs m16,24184,816 19.1%  
Interest coverage x497.064.9 765.5%   
Debt to equity ratio x00.5 0.0%  
Sales to assets ratio x1.60.4 393.8%   
Return on assets %16.010.7 150.1%  
Return on equity %23.422.1 106.1%  
Return on capital %36.319.0 191.5%  
Exports to sales %0.630.7 2.0%   
Imports to sales %12.620.4 62.0%   
Exports (fob) Rs m16210,717 1.5%   
Imports (cif) Rs m3,3227,105 46.8%   
Fx inflow Rs m26811,789 2.3%   
Fx outflow Rs m3,9278,393 46.8%   
Net fx Rs m-3,6593,396 -107.8%   
CASH FLOW
From Operations Rs m2,5145,264 47.8%  
From Investments Rs m-800-9,540 8.4%  
From Financial Activity Rs m-80310,867 -7.4%  
Net Cashflow Rs m9126,591 13.8%  

Share Holding

Indian Promoters % 0.0 40.4 -  
Foreign collaborators % 75.0 20.6 364.1%  
Indian inst/Mut Fund % 7.9 8.4 94.0%  
FIIs % 0.1 10.7 0.9%  
ADR/GDR % 0.0 0.0 -  
Free float % 17.1 19.9 85.9%  
Shareholders   18,270 109,995 16.6%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare ABBOTT INDIA With:   PLETHICO PHARMA  DIVIS LABORATORIES  UNICHEM LAB  ALKEM LABORATORIES  ELDER PHARMA  

Compare ABBOTT INDIA With:   ADCOCK INGRAM (S. Africa)  MYLAN (US)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Vishal Sikka's Infosys Exit, White House Shake up & Cues to Watch Out Today(Pre-Open)

Indian share markets ended lower on Friday but gained during the overall week. At the closing bell on Friday, BSE Sensex closed lower by 271 points and the NSE Nifty finished down 67 points.

Related Views on News

Biocon: Lower Licensing Income Leads to Muted Growth for the Quarter (Quarterly Results Update - Detailed)

Jun 23, 2017

Net Profit lower due to exceptional items in the previous year.

Biocon: High Other Income And Licensing Income Drive Growth (Quarterly Results Update - Detailed)

Nov 7, 2016

Biocon has announced its 2QFY17. The company has reported 19.8% YoY growth in net sales and profits of Rs 1.5 bn for the quarter. Here is our analysis of the results.

Biocon: Lower R&D Expenses Help Margin Expansion (Quarterly Results Update - Detailed)

Sep 19, 2016

Biocon has announced its 1QFY17. The company has reported 21.1% YoY growth in total income and 34.6% YoY increase in net profits. Here is our analysis of the results.

Sun Pharma: Bottomline Slips into the Red Amidst Challenging Environment (Quarterly Results Update - Detailed)

Aug 14, 2017

A challenging environment and one-time expense pushes Sun Pharma into a loss in the first quarter.

Lupin: Bigger Challenges or Bigger Margin of Safety? (Quarterly Results Update - Detailed)

Aug 14, 2017

GST impact coupled with price erosion in US leads to lower profits for the quarter.

More Views on News

Most Popular

A 'Backdoor' to Multibaggers: It's Like Investing in Asian Paints Ten Years Ago(The 5 Minute Wrapup)

Aug 10, 2017

Don't miss these proxy bets on growing companies or in a few years you will be looking back with regret.

The Most Profitable Investment in the History of the World(Vivek Kaul's Diary)

Aug 8, 2017

'Yes, it looks like a bubble. And, yes, it's like buying a lottery ticket. But there's something happening that has never happened before. It's an evolutionary leap in money itself.'

Should You Invest In Bharat-22 ETF? Know Here...(Outside View)

Aug 8, 2017

Bharat-22 is one of the most diverse ETFs offered so far by the Government. Know here if you should invest...

Signs of Life in the India VIX(Daily Profit Hunter)

Aug 12, 2017

The India VIX is up 36% in the last week. Fear has gone up but is still low by historical standards.

Bitcoin Continues Stellar Rise(Chart Of The Day)

Aug 10, 2017

Bitcoin hits an all-time high, is there more upside left?

More

Become A Smarter Investor In
Just 5 Minutes

Multibagger Stocks Guide 2017
Get our special report, Multibagger Stocks Guide (2017 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

ABBOTT INDIA SHARE PRICE


Aug 18, 2017 (Close)

TRACK ABBOTT INDIA

  • Track your investment in ABBOTT INDIA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

ABBOTT INDIA - MERCK LTD COMPARISON

COMPARE ABBOTT INDIA WITH

MARKET STATS